| Safety and Immunogenicity of Preservative Free Inactivated Split Influenza Vaccine, Using the Strain Composition 2006/2007 in Non-Elderly Adult and Elderly Subjects (NCT00354016) | Novartis | 2006-07-01 |
| QuickVue Influenza A+B Clinical Field Trial (NCT00491283) | Quidel Corporation | 2006-07-01 |
| Alternative Oseltamivir Dosing Strategies (NCT00334529) | National Institute of Allergy and Infectious Diseases (NIAID) | 2006-06-05 |
| Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults (NCT00347672) | National Institute of Allergy and Infectious Diseases (NIAID) | 2006-06-01 |
| Safety and Immunogenicity of an Intramuscular Pandemic Influenza Vaccine in Adults and the Elderly (NCT00415129) | Sanofi Pasteur, a Sanofi Company | 2006-06-01 |
| Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy Infants (NCT00348881) | Sanofi Pasteur, a Sanofi Company | 2006-06-01 |
| Immunogenicity, Safety and Tolerability of CSL Limited Inactivated Influenza Vaccine in Adults (NCT00333398) | National Institute of Allergy and Infectious Diseases (NIAID) | 2006-06-01 |
| Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Elderly Subjects (NCT00329927) | Novartis | 2006-06-01 |
| Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older (NCT00329966) | Novartis | 2006-06-01 |
| Study to Evaluate an Influenza Vaccine Candidate (NCT00321373) | GlaxoSmithKline | 2006-05-11 |
| Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above (NCT00319098) | GlaxoSmithKline | 2006-05-01 |
| Clinical Trial of Inactivated Influenza Vaccine (0.5ml Formulation) (NCT01554813) | Hualan Biological Engineering, Inc. | 2006-05-01 |
| Study to Demonstrate the Lot-to-lot Consistency and to Evaluate the Safety of an Adjuvanted Influenza Vaccine Candidate (NCT00321763) | GlaxoSmithKline | 2006-04-27 |
| St. Jude Open Label H5 Trial (NCT00311675) | National Institute of Allergy and Infectious Diseases (NIAID) | 2006-04-01 |
| Study to Evaluate the Safety and Immunogenicity of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) in Adults 18 and 60 Years of Age (NCT00309647) | GlaxoSmithKline | 2006-03-29 |
| Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 Years (NCT00309634) | GlaxoSmithKline | 2006-03-27 |
| Evaluation of the Safety and Effectiveness of a Probiotic Bacterium to Boost the Immune Response to Influenza Vaccines (NCT00294788) | Probiomics Ltd | 2006-03-01 |
| H5 Vaccine Alone or With Adjuvant in Healthy Adults (NCT00296634) | National Institute of Allergy and Infectious Diseases (NIAID) | 2006-03-01 |
| Incidence of Influenza, Downstream Complications of Influenza & Hospitalizations in Elderly Vaccinated With Fluarix™ (NCT00306982) | GlaxoSmithKline | 2006-03-01 |
| T and B Cell Response to Avian Flu Vaccine (NCT00337896) | National Institute of Allergy and Infectious Diseases (NIAID) | 2006-03-01 |
| H5 Vaccine Alone or With Aluminum Hydroxide in Elderly Adults (NCT00294099) | National Institute of Allergy and Infectious Diseases (NIAID) | 2006-03-01 |
| Safety and Dose Study of Peramivir for Influenza Treatment (NCT00297050) | National Institute of Allergy and Infectious Diseases (NIAID) | 2006-02-23 |
| High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza (NCT00298233) | National Institute of Allergy and Infectious Diseases (NIAID) | 2006-02-01 |
| H5 Adult - Chiron Study of Bird Flu Vaccine (NCT00280033) | National Institute of Allergy and Infectious Diseases (NIAID) | 2006-02-01 |
| Comparative Trial Evaluating Safety and Immunogenicity of an Adjuvanted and a Conventional Influenza Vaccine in Elderly Subjects (> 60 Years) (NCT00310648) | Novartis | 2006-01-01 |
| Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Whole Virion, Vero Cell Derived) (NCT00289510) | Alachua Government Services, Inc. | 2006-01-01 |
| Immunogenicity of Two Dosages of Inactivated, Split-Virion Influenza Vaccine Given by an Alternate Route in the Elderly (NCT00296829) | Sanofi Pasteur, a Sanofi Company | 2006-01-01 |
| A/H5N1 Vaccine in Healthy Children Aged 2-9 Years (NCT00133536) | National Institute of Allergy and Infectious Diseases (NIAID) | 2006-01-01 |
| Randomized, Double Blinded, Placebo Control Clinical Trial of Pandemic Influenza Inactive Vaccine on Healthy Subjects (NCT00356798) | Sinovac Biotech Co., Ltd | 2005-12-01 |
| TGV:Use of the Quick Diagnostic Test of the Influenza and the Infection With RSV by the Paediatric Emergency Unit (NCT00263900) | University Hospital, Rouen | 2005-12-01 |
| Study on the Immunogenicity and Tolerability of Influsplit SSW® 2005/2006 in Children Aged 6 - 13 Years (NCT00372255) | GlaxoSmithKline | 2005-11-17 |
| Open Label Evaluation of H5N1 Vaccine at Vaccine Manufacturing Facilities (NCT00311649) | National Institute of Allergy and Infectious Diseases (NIAID) | 2005-11-01 |
| Chart Review of Antivirals for Influenza in Infants (NCT00311701) | National Institute of Allergy and Infectious Diseases (NIAID) | 2005-11-01 |
| Immunogenicity and Safety of Different Doses of Fluzone® Influenza (NCT00253734) | National Institute of Allergy and Infectious Diseases (NIAID) | 2005-11-01 |
| T-cell Response-Flu Risk in Older Adults (NCT00138398) | National Institute of Allergy and Infectious Diseases (NIAID) | 2005-10-25 |
| Safety Study of Four Candidate Influenza Vaccines to Prevent Influenza Disease in the Elderly Population (NCT00318149) | GlaxoSmithKline | 2005-10-10 |
| Safety Study of an Adjuvanted Candidate Influenza Vaccine to Prevent Influenza Disease in the Elderly Population (NCT00318058) | GlaxoSmithKline | 2005-10-03 |
| Study Comparing the Immune Response of Fluarix and Fluzone Influenza Vaccines (NCT00197288) | GlaxoSmithKline | 2005-10-01 |
| Study of a Pandemic Influenza Vaccine (NCT00136331) | Seqirus | 2005-10-01 |
| Cell-Mediated Immune Responses to Influenza A/H5N1 Vaccine (NCT00311727) | National Institute of Allergy and Infectious Diseases (NIAID) | 2005-10-01 |
| Safety and Immunogenicity of Three Commercially Available Influenza Vaccines in Children Aged 6 to <36 Months (NCT00311428) | Novartis | 2005-10-01 |
| Inactivated Influenza A/H5N1 Vaccine in the Elderly (NCT00230750) | National Institute of Allergy and Infectious Diseases (NIAID) | 2005-10-01 |
| Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of Age (NCT00885105) | Sanofi Pasteur, a Sanofi Company | 2005-10-01 |
| Study Comparing Immune Response to, and Safety of, Fluviral and Fluzone Influenza Vaccines in Persons 50 y.o. and Over (NCT00232947) | ID Biomedical Corporation, Quebec | 2005-10-01 |
| H5 Booster After a Two Dose Schedule (NCT00240968) | National Institute of Allergy and Infectious Diseases (NIAID) | 2005-10-01 |
| Liposomal Based Intranasal Influenza Vaccine:Safety and Efficacy (NCT00197301) | Hadassah Medical Organization | 2005-10-01 |
| Revaccination With Subunit Influenza A/Vietnam/1203/2004 (H5N1) Vaccine (NCT00240903) | National Institute of Allergy and Infectious Diseases (NIAID) | 2005-10-01 |
| The Effect of Needle Temperature on Pain Ratings Following Intramuscular Injection (NCT00213967) | University of Wisconsin, Madison | 2005-10-01 |
| Safety and Immunogenicity of 3 Lots of Cell-derived Subunit Influenza Vaccine as Compared to 1 Lot to Egg-derived Subunit Influenza Vaccine in Healthy Adults (>=18 to <=60) (NCT00310804) | Novartis Vaccines | 2005-09-01 |
| Comparison of Safety, Tolerability and Immunogenicity of Influenza Vaccines in Adults and Elderly (NCT00306527) | Novartis Vaccines | 2005-09-01 |
| Post-marketing Study to Evaluate the Efficacy of Influenza Vaccine (NCT00197223) | GlaxoSmithKline | 2005-09-01 |
| Safety and Immunogenicity of the 2005-2006 Fluzone® Vaccine (NCT00258830) | Sanofi Pasteur, a Sanofi Company | 2005-09-01 |
| Immunogenicity Study of the Influenza Vaccine in Adults (NCT00258934) | Sanofi Pasteur, a Sanofi Company | 2005-09-01 |
| Comparison of Delivery Routes of Flu Vaccine in Adults (NCT00170547) | National Institute of Allergy and Infectious Diseases (NIAID) | 2005-09-01 |
| Study of the Protective Effect of an Injectable Influenza Vaccine Against Influenza Illness in Adults Under 50 y.o. (NCT00216242) | ID Biomedical Corporation, Quebec | 2005-09-01 |
| A Phase I Safety and Immunogenicity Study of Mix and Match of Licensed Flu Vaccine and Flumist (NCT00231907) | National Institute of Allergy and Infectious Diseases (NIAID) | 2005-09-01 |
| Comparison of Inactivated and Live, Attenuated Influenza Vaccine in Children 5-9 Years of Age-Year 3 Amendment (NCT00138385) | National Institute of Allergy and Infectious Diseases (NIAID) | 2005-08-01 |
| Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults (NCT00125944) | MedImmune LLC | 2005-07-01 |
| H5N1 Vaccine Intramuscular Versus Intradermal in Healthy Adults (NCT00310206) | National Institute of Allergy and Infectious Diseases (NIAID) | 2005-07-01 |
| Annual Study for Fluarix Registration (NCT00306943) | GlaxoSmithKline | 2005-07-01 |
| Safety and Immunogenicity of an Adjuvanted Influenza Vaccine in Subjects Aged 65 Years and Over. (NCT00316628) | Novartis | 2005-06-01 |
| Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study A) (NCT00110279) | National Institute of Allergy and Infectious Diseases (NIAID) | 2005-06-01 |
| Young Adult Influenza Vaccine Immunogenicity Substudy (NCT00170508) | National Institute of Allergy and Infectious Diseases (NIAID) | 2005-06-01 |
| Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population (NCT00306995) | GlaxoSmithKline | 2005-05-11 |
| Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV) (NCT00111579) | MedImmune LLC | 2005-05-01 |
| Elderly Influenza Vaccine Immunogenicity Substudy (NCT00170482) | National Institute of Allergy and Infectious Diseases (NIAID) | 2005-04-25 |
| Eldery High Dose TIV 2005 (NCT00115531) | National Institute of Allergy and Infectious Diseases (NIAID) | 2005-04-01 |
| Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of Age (NCT00858468) | Sanofi Pasteur, a Sanofi Company | 2005-04-01 |
| A/H5N1in Adult - Aventis (NCT00115986) | National Institute of Allergy and Infectious Diseases (NIAID) | 2005-03-01 |
| A Study of the Safety, Tolerability & Immunogenicity of CSL Limited's Influenza Virus Vaccine In a Paediatric Population (NCT00700193) | Seqirus | 2005-03-01 |
| Inactivated Influenza A/H9N2 Vaccine With and Without MF59 Adjuvant in Ambulatory Adults (NCT00133471) | National Institute of Allergy and Infectious Diseases (NIAID) | 2005-03-01 |
| Evaluation of Alternative Oseltamivir (Tamiflu) Dosing Strategies. (NCT00304434) | US Department of Veterans Affairs | 2005-02-01 |
| Study to Evaluate the Safety, Tolerance and Immunogenicity of Fluviral™ in Healthy Adults (NCT01389479) | GlaxoSmithKline | 2005-01-01 |
| Influenza Vaccine in Lung Transplant Patients - Antibody (NCT04533139) | University of Wisconsin, Madison | 2004-12-01 |
| Influenza Vaccine in Lung Transplant Patients - Seroprotection (NCT04531657) | University of Wisconsin, Madison | 2004-12-01 |
| Influenza Vaccine in Lung Transplant Patients (NCT00205270) | University of Wisconsin, Madison | 2004-12-01 |
| Fluarix Immunogenicity and Safety Trial (NCT00100399) | National Institute of Allergy and Infectious Diseases (NIAID) | 2004-12-01 |
| Influenza Vaccine in Lung Transplant Patients - T Cells (NCT04533061) | University of Wisconsin, Madison | 2004-12-01 |
| Influenza Vaccine in Lung Transplant Patients - Persistence of Antibodies Beyond the Season (NCT04530786) | University of Wisconsin, Madison | 2004-12-01 |
| Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults (NCT00328107) | Protein Sciences Corporation | 2004-11-01 |
| Influenza Vaccine in Pediatric Transplant Subjects (NCT00133510) | National Institute of Allergy and Infectious Diseases (NIAID) | 2004-11-01 |
| Comparison of the Safety and Immune Response of Three Different Lots of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2004/2005 (NCT00161811) | Alachua Government Services, Inc. | 2004-11-01 |
| Comparison of Full-dose Flu Vaccine to Half-dose Flu Vaccine (NCT00283283) | U.S. Army Medical Research and Development Command | 2004-11-01 |
| Trivalent, Live, Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6-59 Months of Age (NCT00128167) | MedImmune LLC | 2004-10-01 |
| Study to Evaluate the Effectiveness of FluMist Vaccination in a School-Based Intervention Program (NCT00192218) | MedImmune LLC | 2004-10-01 |
| FLU-VACS Comparative Study in Adults (NCT00133523) | National Institute of Allergy and Infectious Diseases (NIAID) | 2004-10-01 |
| Inactivated Influenza Vaccine in Infants 10-22 Weeks of Age (NCT00231920) | National Institute of Allergy and Infectious Diseases (NIAID) | 2004-10-01 |
| Safety and Immunogenicity of a Cell Culture-derived Influenza Vaccine in Healthy Adults and Elderly (NCT00492063) | Novartis Vaccines | 2004-09-01 |
| Improving Influenza Vaccination Rates Among Health Care Professionals (NCT00404664) | The Cleveland Clinic | 2004-09-01 |
| Study of Safety and Immunogenicity of Fluzone® in Healthy Children (NCT00831675) | Sanofi Pasteur, a Sanofi Company | 2004-09-01 |
| A Comparison of One Versus Two Doses of Influenza Vaccine in Children 5-8 Years of Age (NCT00158665) | Kaiser Permanente | 2004-08-01 |
| Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma (NCT00307177) | National Institute of Allergy and Infectious Diseases (NIAID) | 2004-08-01 |
| Influenza Vaccine in Lung Transplant Patients - Persistence of Antibodies (NCT04531787) | University of Wisconsin, Madison | 2004-08-01 |
| Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults (NCT00192127) | MedImmune LLC | 2004-08-01 |
| Safety and Immunogenicity of the World Health Organization (WHO) Formulation of the 2004-2005 Fluzone® Vaccine (NCT00831987) | Sanofi Pasteur, a Sanofi Company | 2004-08-01 |
| Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age (NCT00192140) | MedImmune LLC | 2004-06-01 |
| Rapid Vaccination of Hard-To-Reach Populations (NCT00155974) | The New York Academy of Medicine | 2004-02-01 |
| Comparison of the Safety and Immune Response of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2003/2004 (NCT00161837) | Alachua Government Services, Inc. | 2003-12-01 |
| Study to Monitor the Safety and Reactogenicity of Fluarix™ in Korean Subjects Aged > 6 Months of Age. (NCT00750360) | GlaxoSmithKline | 2003-10-03 |
| Immuno & Reacto of TF Trivalent Influenza Split Vaccine 2003/04 or of Std Formulation Influsplit SSW®/Fluarix™ 2003/04 (NCT00731393) | GlaxoSmithKline | 2003-10-01 |